Antioxidant status and lipid peroxidation in the blood of breast cancer patients of different ages after chemotherapy with 5-fluorouracil, doxorubicin and cyclophosphamide

被引:53
|
作者
Kasapovic, Jelena [1 ]
Pejic, Snezana [1 ]
Stojiljkovic, Vesna [1 ]
Todorovic, Ana [1 ]
Radosevic-Jelic, Ljiljana [2 ]
Saicic, Zorica S. [3 ]
Pajovic, Snezana B. [1 ]
机构
[1] Univ Belgrade, Vinca Inst Nucl Sci, Lab Mol Biol & Endocrinol, Belgrade 11000, Serbia
[2] Univ Belgrade, Inst Oncol & Radiol Serbia, Belgrade, Serbia
[3] Univ Belgrade, Inst Biol Res Sinisa Stankovic, Dept Physiol, Belgrade, Serbia
关键词
Lipid peroxidation; Antioxidants; Breast cancer; Chemotherapy; Radiotherapy; Aging; OXIDATIVE STRESS; PLASMA; RADIOTHERAPY; ADRIAMYCIN; APOPTOSIS; SYSTEM;
D O I
10.1016/j.clinbiochem.2010.08.009
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Objectives: Breast carcinoma is related to the increase of lipid peroxidation in plasma with concomitant decrease of antioxidant (AO) defense capacity in blood cells, which becomes more pronounced during aging of the patients. This work evaluated the potential age-related effect of chemotherapy with 5-fluorouracil, doxorubicin and cyclophosphamide (FAC) on the level of lipid hydroperoxides (LP), glutathione (GSH), AO enzyme activities of copper, zinc superoxide dismutase (CuZnSOD), catalase (CAT), glutathione peroxidase (GPx), and glutathione reductase (GR) in breast cancer patients. The level of CuZnSOD protein was assessed after the FAC therapy and radiotherapy of breast cancer. Design and methods: AO parameters were measured in the blood of 58 breast cancer patients and 60 healthy age-matched healthy subjects by biochemical and Western blot analyses. Results: Increased oxidative stress (LP: p<0.05) and decreased AO enzyme activities (CuZnSOD: p<0.01, GPx: p<0.05, GR: p<0.01) and GSH level (p<0.01) in the blood of breast cancer patients in response to FAC chemotherapy seem not to be age-dependent. CuZnSOD enzyme expression decreased after the FAC chemotherapy (p<0.05), while it increased after the radiotherapy of breast cancer (p<0.05). Conclusion: FAC chemotherapy and radiotherapy promote further oxidative shift, which potentiate already existing chronic oxidative stress linked to breast cancer. In these effects, impaired capacity for H2O2 detoxification (CAT. GPX and GSH) seems to have major contribution. (C) 2010 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:1287 / 1293
页数:7
相关论文
共 50 条
  • [21] Lipid peroxidation and antioxidant status in blood of rheumatoid arthritis patients
    D. Vijayakumar
    K. Suresh
    S. Manoharan
    Indian Journal of Clinical Biochemistry, 2006, 21 (1)
  • [22] Prospective randomized trial of 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus paclitaxel and FAC (TFAC) in patients with operable breast cancer: impact of taxane chemotherapy on locoregional control
    Albert, Jeffrey M.
    Buzdar, Aman U.
    Guzman, Reina
    Allen, Pamela K.
    Strom, Eric A.
    Perkins, George H.
    Woodward, Wendy A.
    Hoffman, Karen E.
    Tereffe, Welela
    Hunt, Kelly K.
    Buchholz, Thomas A.
    Oh, Julia L.
    BREAST CANCER RESEARCH AND TREATMENT, 2011, 128 (02) : 421 - 427
  • [23] LIPID PEROXIDATION AND ANTIOXIDANT STATUS IN BLOOD OF RHEUMATOID ARTHRITIS PATIENTS
    Vijayakumar, D.
    Suresh, K.
    Manoharan, S.
    INDIAN JOURNAL OF CLINICAL BIOCHEMISTRY, 2006, 21 (01) : 104 - +
  • [24] Neoadjuvant 5-fluorouracil, epirubicin and cyclophosphamide chemotherapy followed by docetaxel in refractory patients with locally advanced breast cancer
    Heller, W.
    Mazhar, D.
    Ward, R.
    Sinnett, H. D.
    Lowdell, C.
    Phillips, R.
    Shousha, S.
    Fayaz, A.
    Palmieri, C.
    Coombes, R. C.
    ONCOLOGY REPORTS, 2007, 17 (01) : 253 - 259
  • [25] Systemic immune effects of adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide and/or radiotherapy in breast cancer: a longitudinal study
    Mozaffari, Fariba
    Lindemalm, Christina
    Choudhury, Aniruddha
    Granstam-Bjorneklett, Helena
    Lekander, Mats
    Nilsson, Bo
    Ojutkangas, Marja-Leena
    Osterborg, Anders
    Bergkvist, Leif
    Mellstedt, Hakan
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2009, 58 (01) : 111 - 120
  • [26] Systemic immune effects of adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide and/or radiotherapy in breast cancer: a longitudinal study
    Fariba Mozaffari
    Christina Lindemalm
    Aniruddha Choudhury
    Helena Granstam-Björneklett
    Mats Lekander
    Bo Nilsson
    Marja-Leena Ojutkangas
    Anders Österborg
    Leif Bergkvist
    Håkan Mellstedt
    Cancer Immunology, Immunotherapy, 2009, 58 : 111 - 120
  • [27] Role of Cathepsin D in Monitoring Breast Cancer Treatment Using Doxorubicin in Combinations with Cyclophosphamide and 5-Fluorouracil
    Malik, Rukhsana
    Saqib, Muddassara
    Talat, Aisha
    PAKISTAN JOURNAL OF MEDICAL & HEALTH SCIENCES, 2016, 10 (02): : 360 - 363
  • [28] Prospective randomized study of cyclophosphamide, epirubicin, and 5-fluorouracil versus cyclophosphamide, adriamycin, and 5-fluorouracil in advanced or recurrent breast cancer
    Kobayashi T.
    Koyama H.
    Oka T.
    Yasumura T.
    Kan N.
    Takatsuka Y.
    Noguchi M.
    Morimoto K.
    Suzuki T.
    Tobe T.
    Mori T.
    Breast Cancer, 1999, 6 (1) : 37 - 42
  • [29] A PHASE-III RANDOMIZED TRIAL OC CYCLOPHOSPHAMIDE, MITOXANTRONE, AND 5-FLUOROURACIL (CNF) VERSUS CYCLOPHOSPHAMIDE, ADRIAMYCIN, AND 5-FLUOROURACIL (CAF) IN PATIENTS WITH METASTATIC BREAST-CANCER
    ALONSO, MC
    TABERNERO, JM
    OJEDA, B
    LLANOS, M
    SOLA, C
    CLIMENT, MA
    SEGUI, MA
    LOPEZ, JJ
    BREAST CANCER RESEARCH AND TREATMENT, 1995, 34 (01) : 15 - 24
  • [30] Combinatorial Effects of Chrysin with Doxorubicin, 5-Fluorouracil, and Cyclophosphamide on Triple-Negative Breast Cancer Cell Line
    Yosefi, Sedighe
    Madanchi, Hamid
    Pakdel, Abbas
    Kokhaei, Parviz
    Hemati, Maral
    Sarmadi, Negar
    Sirati-Sabet, Majid
    IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH, 2025, 24 (01):